Teva Pharmaceutical Industries Ltd (NASDAQ:
TEVA) reports its Q4 non-GAAP EPS at $1.25, versus the consensus of $1.28. TEVA reports its Q4 revenue at $4.42 billion, versus the consensus of $4.64 billion.
TEVA shares dropped 2.89% to $53.39 in pre-market trading.
Read more
from Benzinga's Company news.© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
